ArticleInternational urogynecology journal2025
Incidence and Outcomes of Occult Uterine Cancer in Uteri Removed for Prolapse.
Article in International urogynecology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on: Incidence and Outcomes of Occult Uterine Cancer in Uteri Removed for Prolapse-Can We Define a "Very Low-Risk" Occult Endometrial Cancer Phenotype?International urogynecology journal · 2026Article
- Clinically Significant Occult Uterine and Cervical Pathology in Women Undergoing Minimally Invasive Sacrocolpopexy With Concomitant Total Hysterectomy: A Retrospective Consecutive Case Series.International urogynecology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisTo identify the incidence of occult endometrial cancer diagnosed following hysterectomy for the repair of pelvic organ prolapse, and compare patient outcomes to a control cohort of preoperatively diagnosed endometrial cancer patients.
methodsA retrospective cohort study of patients ≥50 years with endometrial cancer between 2010 and 2020 was performed. Demographic, clinical, surgical, and oncologic variables were compared between occult endometrial cancer and preoperatively diagnosed endometrial cancer cohorts.
resultsOne thousand seventy-two patients were included, of which 30 (2.8%) had occult endometrial cancer diagnosed after prolapse surgery and 1042 (97.2%) were in the preoperatively diagnosed historic cohort. The incidence of occult endometrial cancer was 0.56% for all hysterectomies performed for pelvic organ prolapse. Patients in the occult endometrial cancer cohort were more likely to have grade I disease (85.2% vs. 52.1%, p < 0.001), less likely to have lymphovascular space invasion (10.7% vs. 31.8%) or >50% myometrial invasion (11.1% vs. 24.0%, p = 0.004) compared to the preoperatively diagnosed patients. Ten occult endometrial cancer patients (33.3%) underwent a second staging procedure; 83.3% (n = 25) of patients received care in compliance with comprehensive national cancer guidelines. Five-year recurrence free survival was 95.0% (95% CI 85.4-100%) and 66.8% (95% CI 59.3-74.4%) for preoperatively diagnosed cohort and occult endometrial cancer cohort, respectively, while 5-year overall survival was 90.9% (95% CI 78.9-100%) and 83.0% (95% CI 75.5-90.5%), respectively.
conclusionsThe rate of incidental endometrial cancer after hysterectomy for pelvic organ prolapse was 0.56% in our cohort. Most occult diagnosed patients are diagnosed with early-stage and low-grade disease. The majority received care concurrent with National Comprehensive Cancer Network recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.